BCLC Stage C Hepatocellular Carcinoma Clinical Trial
Official title:
Three-arm Open Parallel Control Phase II Trial for Evaluation of Thermal Ablation Combined With Apatinib and PD-1 Antibody SHR-1210 for Advanced Liver Cancer
The purpose of this study was to evaluate the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for the treatment of advanced liver cancer.
Primary liver cancer is a common malignant tumor in the world. Its pathogenesis is concealed
and clinically asymptomatic. It is mostly in the middle and late stages of the disease. It is
often combined with different degrees of cirrhosis. The liver function reserve is poor.About
80% of patients are in the first place. The operation has been lost at the time of diagnosis.
Primary liver cancer is not sensitive to conventional treatments such as radiotherapy and
chemotherapy because of its unique tissue type. For advanced liver cancer, ablation combined
with other systemic treatments is expected to alleviate the patient's condition, prolong the
patient's survival time, and benefit more patients. The long-term clinical efficacy of tumor
thermal ablation has been reported more, the basic conclusion is consistent, hat is, the
5-year survival rate of early stage tumors such as liver cancer less than 3cm is not inferior
to surgical resection, or even better. Liver cancer is rich in blood supply and tumor blood
vessels are dense. The formation and maintenance of these blood vessels requires
pro-angiogenic signals, of which VEGFR is a key component. Apatinib is a small molecule
tyrosine kinase inhibitor that inhibits VEGFR at very low concentrations. SHR-1210 is a
humanized anti-programmed cell death receptor 1 antibody.
This study was designed to evaluate the efficacy and safety of simple local ablation, local
ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody
SHR-1210 for the treatment of advanced liver cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01900002 -
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Terminated |
NCT04777708 -
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04828486 -
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
|
Phase 2 | |
| Recruiting |
NCT04736121 -
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
|
N/A | |
| Not yet recruiting |
NCT05810402 -
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
|
N/A | |
| Recruiting |
NCT06172205 -
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
|
Phase 3 | |
| Recruiting |
NCT05199285 -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
|
Phase 2 | |
| Completed |
NCT02940496 -
Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer
|
Phase 2 | |
| Withdrawn |
NCT05327738 -
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04605731 -
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
|
Phase 1 | |
| Recruiting |
NCT04992143 -
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
|
Phase 2 | |
| Recruiting |
NCT05250895 -
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients With Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
|
Early Phase 1 | |
| Terminated |
NCT04442581 -
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
|
Phase 2 |